Jace Therapeutics

Jace Therapeutics is a pre-clinical stage biotechnology company focused on developing small molecule inhibitors that target the Integrated Stress Response (ISR) pathway to treat cancer and other diseases. Founded by leading researchers from the University of Pennsylvania, the company leverages deep expertise in the PERK and GCN2 kinase pathways, which are critical for cellular adaptation to stress. Their lead programs aim to disrupt the ability of tumor cells to survive in harsh microenvironments, potentially enhancing the efficacy of existing immunotherapies. By modulating protein synthesis and cellular homeostasis, Jace Therapeutics seeks to provide new therapeutic options for patients with hard-to-treat solid tumors.